Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …

Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Clinical investigation of poly (ADP-ribose) polymerase (PARP) inhibitors for ovarian cancer
treatment has rapidly evolved from observations of single-agent in vitro activity of these …

Background Niraparib is an oral poly (adenosine diphosphate [ADP]–ribose) polymerase
(PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We …

Purpose We evaluated the efficacy and safety of bevacizumab in patients with platinum-
resistant epithelial ovarian carcinoma (EOC) or peritoneal serous carcinoma (PSC) who had …

Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of
Bereaved Caregivers' Mental Health - PMC Back to Top Skip to main content NIH NLM Logo …

Cytotoxic chemotherapy targets elements common to all nucleated human cells, such as
DNA and microtubules, yet it selectively kills tumor cells. Here we show that clinical …

Importance Immune checkpoint inhibitor therapy has shown benefit in various cancers, but
their potential in endometrial cancer (EC) is unknown. Observations Prediction of …

Immune checkpoint inhibitors (eg, anti-PD-1 and anti-PD-L1 antibodies) have demonstrated
remarkable efficacy against hypermutated cancers such as melanomas and lung …

BACKGROUND: Hypersensitivity reactions (HSRs) to chemotherapeutic drugs, including
mAbs, often require that the provoking medication be discontinued, thus raising a dilemma …